



IFW
CP

Attorney Docket No. 2543-1-033

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Jonathan A. Terrett

SERIAL NO.: 10/736,227

EXAMINER: Unassigned

DATE FILED: December 15, 2003

ART UNIT: 1645

FOR: NOVEL CANCER ASSOCIATED PROTEIN

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2004.

Karen Garipoli
(Name of Depositor)

Karen Garipoli 6/30/04
(Signature and Date)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References BA through CO listed on the attached Form

PTO-1449. However, with respect to Reference **BC**, please note that due to the size of the reference (367 pages), a CD containing reference WO 02/64611 in Adobe .pdf format is enclosed in place of a printed copy. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,



David A. Jackson
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON
411 Hackensack Avenue
Hackensack, New Jersey 07601
201-487-5800



Sheet 1 of 2

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-033
	SERIAL NO.	10/736,227
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	WO 01/13117A2 & A3 (EP 1208381)	2/22/01	PCT			
	BB	WO 00/55628 (EP 1159618)	9/21/00	PCT			
	BC	WO 02/64611	8/22/02	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CA	Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™)Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts ¹ , 1998, Cancer Res. 58: 2825-2831
	CB	Catimel, B., et al., Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium,1996, J. Biol. Chem. 271:25664-25670
	CC	ABSTRACT for Craggs, et al., 2003, Applied Genomics & Proteomics 2(2):101-100
	CD	Davis, ID,et al.,An overview of Cancer immunotherapy,2000, Immunol Cell Biol. 78: 179-196
	CE	Dillman, R.O.,Perceptions of Herceptin®:A Monoclonal Antibody for the Treatment of Breast Cancer,1999, Cancer Biother. Radiopham. 14: 5-10
	CF	Green,MC,etal,Monoclonal antibody therapy for solid tumors,2000,Cancer Treat Rev 26:269-86
	CG	Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528
	CH	Knuth, A. et al., Cancer immunotherapy in clinical oncology,2000, Cancer Chemother. Pharmacol. 46, S46-51

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;
Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY. DOCKET NO.	2543-1-033
	SERIAL NO.	10/736,227
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CI	Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression, 2000, Int.J. Cancer 87:55-60
	CJ	Miller, K.D., et al., Toward checkmate:biology and breast cancer therapy for the new millennium, 1999, Invest.New Drugs 17: 417-427
	CK	Saffran, D.C., et al.,Targget antigens for prostate cancer immunotherapy, 1999, Cancer Metastasis Rev. 18: 437-449
	CL	Shiku, H., et al.,Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82
	CM	Stebbing, J., et al.,Herceptin (trastuzumab) in advanced breast cancer, 2000, Cancer Treat. Rev. 26:287-290
	CN	Vermeulen, S.J., et al., The α E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells, 1999, Oncogene 18: 905-915
	CO	Database EMBL online 1December 2001(2001-12-01)"NSE2 Protein" Database Accession No. Q96Kn1 XP002234948
EXAMINER:		DATE CONSIDERED:
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>		